1. Introduction {#sec1}
===============

*Chironex fleckeri* is a large box jellyfish commonly found in Australia waters, and suspected through out the Indo Pacific region ([@bib5a], [@bib6a], [@bib54], [@bib4a]). *C. fleckeri* has one of the most lethal and rapidly active venoms known ([@bib3], [@bib51], [@bib54]; [@bib162]). *C. fleckeri* has caused 77 known fatal stings in the last century ([@bib21], [@bib40]) and with the greatest risk of envenoming occurring in northern Australian waters from October through May, though fatalities have been recorded in every month of the year except July ([@bib23]). Nearly all envenomations occurred in shallow water beaches, 92% of stings occurred between October through June ([@bib22]).

Envenomation occurs at the epidermis, with jellyfish tentacles releasing hundreds of millions of nematocysts per sting ([Fig. 1](#fig1){ref-type="fig"}). Nematocysts are biological syringes that eject small molecules, lipids, carbohydrates, proteins and small molecules into prey with harpoon-like protrusions that may be activated upon mechanical, osmotic, chemical and neuronal reception ([@bib2a]). Clinical reports of non-fatal *C. fleckeri* envenomation have contributed to the understanding of systemic venom effects including severe pain, urticaria and scarring from nematocyst contact, hypotension, vasospasms, cardiac irregularities and acute onset of cardiac arrest ([@bib15], [@bib18], [@bib45]). There are no standard treatment options for *C. fleckeri* and envenomation given the pathomechanisms are unknown. A randomized controlled trial found no difference in efficacy between icepacks and hot water immersion in reducing pain ([@bib35]). Other treatments have been trialed including vinegar application, opioids and antivenom ([@bib22], [@bib14]) (see [Fig. 2](#fig2){ref-type="fig"}).Fig. 1***C. fleckeri* tentacle nematocysts firing.***C. fleckeri* nematocyst spikes imaged *in vitro* using a high speed phantom VEO camera <https://biopixel.tv/>.Fig. 1Fig. 2**Clinical symptoms and mechanisms underlying *C. fleckeri* envenomation.** Flow chart includes known physiological responses to *C. fleckeri* envenomation in case studies or *in vivo* and highlights unknown mechanisms of action associated with these responses.Fig. 2

Given the potency and extremely rapid activity of *C. fleckeri* venom, it is interesting to note that many of these venom proteins have not been described in current gene or protein databases ([@bib3], [@bib11], [@bib10], [@bib13], [@bib51], [@bib54]). *C. fleckeri* venom has pore-forming proteins and is considered hemolytic, it may also have ion channel modulating characteristics ([@bib3], [@bib13], [@bib15], [@bib44]). Mechanism of action studies on *C. fleckeri* venom have suggested ionophoric effects ([@bib3], [@bib29], [@bib44], [@bib59]) and more research is needed. Given the potency and evolutionary distinctiveness of *C. fleckeri* venom, there is potential for venom-derived drug discovery and development (circulatory medicine etc.). Further study of this venom\'s mode of action may lead to effective standard treatments. This review summarises what is known on the mechanism of *C. fleckeri* action and highlights knowledge gaps.

2. Animal pathophysiology following *C. fleckeri* envenomation {#sec2}
==============================================================

Animal studies found that *C. fleckeri* venom had potent effects on the cardiovascular and pulmonary systems ([@bib29], [@bib49], [@bib50], [@bib55]). Effects included dramatic changes in arterial and venous pressure, heart rate, and abdominal respiratory physiology in anaesthetised rabbits and mice post exposure. *C. fleckeri* was extremely potent in extremely small volumes (0.1 mL of a 5,000-fold dilution of tentacle extract) and was enough to kill a mouse within 2 min ([@bib29]). Rabbits challenged with *C. fleckeri* venom exhibited survival times between 1 and 6 min. The physiological effects in rabbits comprised: (i) bi-phasic blood pressure changes with resting arterial pressure rising from 115 mmHg to 140 mmHg in 8 s; (ii) A plummet in arterial pressure to 225 mmHg followed a spike in 90 s; (iii) Apnea followed hypoxia; (iv) Respiratory failure and acute hypotension; (v) Bradycardia and a T-wave inversion; (vi) Arterial pressure failure and deteriorating heart rates (from 260 to 340 beats/min to 100--150 beats/min) and; (vii) Finally, terminal respiratory failure ([@bib29], [@bib30]). These effects have been replicated in other studies ([@bib15], [@bib33], [@bib55]). While the animal response to *C. fleckeri* venom has been well documented, clinical case reports are limited to describing basic symptoms such as welts on the epidermis or the cardiotoxic effects from fatalities ([@bib22]).

3. The effects of antivenom on *C. fleckeri* envenomation {#sec3}
=========================================================

No one nationwide recommendation for first-aid can be made due to differences between jellyfish species. It was hoped that treatment with antivenom would prevent effects seen in severe envenomation by neutralising causative toxins in the venom. The Commonwealth Serum Laboratories (CSL) first produced *C. fleckeri* antivenom in the 1970s using hyper-immunized sheep ([@bib5], [@bib24]) and continue to produce antivenom. However, *C. fleckeri* antivenom efficacy has been called into question through data from animals and patients ([@bib23], [@bib24], [@bib27], [@bib42], [@bib47], [@bib59], [@bib60]).

Studies using antivenom treatment post *C. fleckeri* venom challenge have produced varying results. In one study, mice administered antivenom after *C. fleckeri* venom challenge showed 7% survival ([@bib27]). However, another study showed 59% survival after *C. fleckeri* venom challenge ([@bib14]). These findings were confirmed in a related study ([@bib60]). Using rat aortic smooth muscle cell line, *C. fleckeri* antivenom treatment showed no neutralisation ([@bib42]). Interestingly, a dose study reported that the high amounts of antivenom did not improve protection in piglets ([@bib55]) suggesting a concentration limit for efficacy. These results were confirmed in another study which showed the antivenom was effective within a limited dose range ([@bib2], [@bib8]).

Due to the underwhelming effects of antivenom in animal models, researchers next examined antivenom prophylactically. Prophylactic use of antivenom prolonged the survival time of mice by 5-fold ([@bib27]). A separate study showed that while prophylactic administration of antivenom did not have any effect on blood pressure after envenomation, the antivenom did prevent cardiovascular collapse in 40% of test animals ([@bib48]). In contrast, another prophylactic study reported improved arterial pressure post low dose administration ([@bib33], [@bib48], [@bib59]). In a follow up study, antivenom given 15 min before venom delivery did not prevent cardiovascular collapse and a very high dose was unable to attenuate venom effects ([@bib60]). In addition, antivenom administered with magnesium sulfate could prevent cardiovascular collapse ([@bib48]). Collectively, prophylactic administration of antivenom shows varying effects and is impractical.

Another methodology was to combine *C. fleckeri* venom with antivenom and administer the mixture. This improved cell survival *in vitro* and improved animal survival ([@bib2], [@bib42], [@bib55], [@bib60]). In a related study, CSL antibodies were compared with polyclonal rabbit antibodies raised against nematocyst-derived venom ([@bib60]). Neither were effective therapeutically. Again, mixing *C. fleckeri* venom with antivenom is an impractical solution.

There is currently no consensus on how much antivenom is required to be effective. From animal data, effective antivenom amounts would be 3--4 fold higher than is suggested for humans ([@bib2], [@bib27]). Two studies have reported risk of adverse reactions at low antivenom doses ([@bib53], [@bib58]) and a clinical case study in Australia reported that only 5% of patients received antivenom for *C. fleckeri* envenomation ([@bib24]). In addition to these data, there has been 4 fatalities even after the use of antivenom ([@bib24]).

4. Experimental and combination therapies for *C. fleckeri* envenomation {#sec4}
========================================================================

The effects of *C. fleckeri* venom on small mammalian physiology have been examined with various experimental therapeutics ([@bib8], [@bib12], [@bib15], [@bib29], [@bib36], [@bib37], [@bib49], [@bib50], [@bib54]). Due to the effects on the cardiovascular and pulmonary systems, one study looked at the combined effect of antivenom with Verapamil. Verapamil is a calcium channel blocker which has been shown to relax the muscles of the heart and is used to treat high blood pressure, angina, and cardiac arrhythmias ([@bib14], [@bib31]). Post injection with *C. fleckeri* venom, all untreated mice died within 7.5 min of venom administration. Here, 59% of the animals administered antivenom died within 3 min, 68% of the animals administered Verapamil died within 24 min, and 26% of mice given a mixture of antivenom and Verapamil died within 34 min ([@bib14]). Thus, Verapamil exhibited prolonged survival times. A related study attempted a rescue experiment post envenomation using a combination of antivenom and Verapamil ([@bib8]). This treatment nearly doubled the survival time.

However, addition of verapamil to a higher dose of antivenom did not increase survival time. Antivenom alone was shown ineffective. These findings were confirmed in a similar study ([@bib60]).

Additional studies using Verapamil have also shown inconsistent results prophylactically and therapeutically ([@bib14], [@bib36], [@bib55]). It was additionally noted that Verapamil may cause hypotension, vasodilation and have adverse inotropic effects ([@bib55]). However, another calcium channel blocker, Felodipine, was able to block the *C. fleckeri* venom effects *in vitro* (further detailed in section [5](#sec5){ref-type="sec"}) ([@bib59]). Collectively, the results of *C. fleckeri* venom treatment have been inconsistent both *in vitro* and *in vivo*.

5. Consistencies and variabilities in animal testing {#sec5}
====================================================

Overall, the above animal studies consistently found *C. fleckeri* venom caused the following effects in mice, rats, rabbits, and piglets: (i) bi-phasic pressor responses with extreme hypertension followed by hypotension and; (ii) cardiovascular collapse and cardiotoxicity characterised by electrophysiology dysfunction with survival times as short as 1--2 min. One aspect that makes comparing results between studies difficult is varying concentrations of venom used in testing. Importantly, historical animal studies did not report venom profiles which may contribute to the variability between results. Two aspects that contribute to the venom profile are, collection site and ontogenetic variations. For instance, *C. fleckeri* venom from Weipa, Australia was found to be more lethal compared with venom taken from Mission Beach, Australia, a location nine hundred kilometres south ([@bib11], [@bib60]). The size of the jellyfish is also relevant. Extremely potent cardiotoxic venom has been observed in large *C. fleckeri* samples ([@bib11], [@bib43]). In future, it would be informative to examine *C. fleckeri* specimens from multiple regions across Australian waters.

The only common finding from these above experiments is the rapid action of the venom. Treatments either increased survival times ([@bib8]) or not ([@bib14]). These inconsistencies may arise from several factors that could be attributed to venom geography/profile/preparation rather than variation in methodology. The venom profile in each of these studies was not documented and likely would have varied due to different venom extraction techniques. For example, an *in vitro* and an *in vivo* study showed inconsistent results of Verapamil ([@bib8]). Another calcium channel blocker, Felodipine (T-type calcium channel blocker), significantly reduced the contractile force in isolated rat aorta ([@bib59]). The most effective treatments shown thus far are all based on ionophoric mechanisms ([@bib3], [@bib44], [@bib29]). Non-specific voltage gated calcium channels may be involved rather than L-type voltage gated calcium channels. Immunisation has been considered as a treatment for *C. fleckeri* venom ([@bib1]). Whether this is practical or cost effective is unlikely.

6. The divergent methods of C. *fleckeri* venom extraction {#sec6}
==========================================================

Isolating pure venom from jellyfish tentacles has presented a significant challenge for researchers. The capsular organelles that deliver the venom have highly specialised anatomy and there are several classes of nematocysts ([@bib14a]). Researchers have attempted numerous isolation techniques. The first venom extraction method was from milked venom ([@bib4]). While this collection technique was aimed to imitate natural envenomation, the authors reported the resulting material was contaminated with amniotic proteins and resulted in low antivenom yields from immunized animals.

The first mechanical activation of nematocysts involved mortar and pestle grinding in ice and filtered seawater, which resulted in low venom yields ([@bib26]). Subsequent mechanical disruption of nematocysts involved whole tentacle homogenisation that was centrifuged at low temperatures termed "homogenate venom extraction" ([@bib29]). Another technique was beachside separation of tentacle material from nematocysts. This was performed by refrigerating tentacles in sea water for 1--4 days. Nematocysts were separated from debris in solution with a fine sieve and preserved in aliquots for freezing ([@bib7]). Other mechanical extraction techniques separated the nematocysts from the tentacle and then activated the nematocysts. This technique was termed "crude venom extraction". Yet another example was the use of sonar or high frequency sound to rupture the nematocyst capsular organelles ([@bib15], [@bib44]). Many early mechanical disruption techniques involved grinding nematocysts for long periods which exposed the venom to protracted raised temperatures ([@bib26]). This lead to the discovery of the thermolabile nature of *C. fleckeri* venom ([@bib7], [@bib15], [@bib16], [@bib26]).

Researchers have also explored chemical extraction. One method, soaked tentacles in ethanol for 24hr to activate nematocysts ([@bib39]). This extraction method allowed venom collection in one step and revealed novel proteins. However, it is likely that exposing the venom to strong alcohol would lead to protein degradation. Since heat and chemical extraction techniques rendered venom components to degradation, a cold mechanical method was developed ([@bib16]). This protocol involved soaking tentacles in sea water for five days which caused nematocysts to detach from the tentacles. A strainer was then used to separate the nematocysts from the soaking solution. The strained solution was centrifuged and the nematocyst pellet was placed into a mini-glass-bead beater. The mechanical agitation of the nematocysts was repeated to allow for maximum venom yield. The process took place in a cold room to ensure nematocysts remained temperature stable throughout. The venom was then pipetted off and passed through a micro filter before experimental use. Another method used both chemical and ethanol extraction to obtain purified porin fractions of the *C. fleckeri* venom ([@bib61]). The study used this technique *in vitro* and *in vivo* and concluded that a pore forming mechanism must be the foremost mechanism of action of *C. fleckeri* whole venom. Hydrolysis was not observed and this extraction method may not reflect the results observed in the natural setting given it alters venom compounds.

Another study aimed to investigate the mechanism responsible for the hallmark bi-phasic blood pressure response to *C. fleckeri* envenomation from two different venom samples from separate extraction techniques ([@bib50]). They showed that a pure sample extracted from nematocysts versus tentacle extact had pharmacologically distinct cardiovascular effects in rodents.

These differing extraction methods have shown that *C. fleckeri* venom activity is sensitive to changes in heat, freezing, thawing and blunt-force grinding. Many methods effect venom composition and/or generate low yields ([@bib8], [@bib16], [@bib26], [@bib46], [@bib49], [@bib50], [@bib15a]). Thus, a significant barrier to progress is the lack of standardisation of venom extraction. A standardised method for venom extraction that has minimal-to-no impact on venom composition will allow for more robust and replicable experiments between research sites.

7. The 'omics' of *C. fleckeri* venom {#sec7}
=====================================

The transcriptomics and proteomics of *C. fleckeri* venom is complex. Studies using SDS-page gel have identified two proteins of interest, CfTX-1 and CfTX-2 ([@bib9]). These proteins are hemolytic or pore-forming toxins that have close homology with three other box jellyfish species, *Chiropsalmus quadrigatus*, *Carybdea rastoni* and *Alatina alata* which are also known to show hemolytic properties in their venom ([@bib9]). The conserved amino acid region (TSR1) found in *C. fleckeri* and other cubozoan toxins, may be responsible for the pore forming action of these toxins ([@bib9], [@bib25]). Fractionation of *C. fleckeri* venom using size exclusion and cation exchange chromatography revealed further complexity through the identification of three additional toxins, CfTX-A, CfTX-B and CfTX-Bt. Here, CfTX-2 was referred to as Type I toxin and CfTX-1and CfTX-2 were referred to as Type II toxins ([@bib11]). These two toxin types were determined using bioinformatics based on phylogenetic similarities. Type II toxins showed close structural homology to a 3d-Cry toxin, which are known to induce cell lysis and death through pore forming action ([@bib11]).

Finally, a recent transcriptomic and proteomic study of C. *fleckeri* venom revealed \~20,000 predicted proteins and over 150 potential toxins by transcriptomics. Over 250 proteins were revealed by LC MS/MS with the most abundant proteins having little-to-no blast homology to known animal or plant proteins ([@bib10]).

8. The varying mechanisms of action from *C. fleckeri* venom fractions {#sec8}
======================================================================

One of the first studies to provide insight into the molecular mechanism of *C. fleckeri* envenomation was a study on the effect on cardiac transmembrane potentials ([@bib28]). Dissections of rabbit and guinea pig hearts were perfused with two fractions of *C. fleckeri* venom obtained via size exclusion chromatography and were termed cardiotoxin and haemolytic/cardio toxin. The cardiotoxin reduced atrial action potential spike height, maximal diastolic potential and maximal rate of rise of action potential. Effects of the cardiotoxin on right atrial preparations showed sinoatrial (SA) and atrioventricular (AV) node depression, thus producing an action potential. That would undershoot normal contestations. It was suggested that these changes were the effects of increased sodium permeability in the cell. Indeed, it had been previously shown that the inhibition of depolarization of Purkinje fibers with a sodium ion channel blocker, Tetrodotoxin (TTX), would restore cardiac action potentials ([@bib32]). TTX was trialed to attenuate the effects of *C. fleckeri* venom fractions with minor effects ([@bib28]). Interestingly, washing the tissue was found to reverse the cardiotoxic effects, but the cardiotoxin and haemolytic toxin fraction combination was non-reversible. Thus, it was concluded that venom fractions contained distinct proteins, and that the two fractions exerted effects by different mechanisms. A more recent study showed similar findings. *Chironex fleckeri* venom was fractionated using fast protein liquid chromatography to isolate the cardiotoxic proteins of the venom which revealed new subfractions from CfTX-1 or CfTX-2 ([@bib19]). Three subfractions were identified comprising CTF-α, CTF-β, and CTF-γ. A cell metabolism assay was used to monitor the effects of the fractions on human skeletal muscle cell and cardiac myocyte metabolism. This study found that CTF-α and, CTF-β were cytotoxic to cardiac myocytes and not skeletal muscle cells. CTF-α and CTF-β were observed to have a synergistic effect causing faster and permanent cell detachment and death than either toxin fraction alone. The third fraction, CTF-γ, was toxic to muscle cells but not cardiomyocytes. Since the study observed cellular recovery after 3 h, they concluded their findings did not align completely with a pore forming mechanism of action ([@bib19]).

9. Ionophoric action as a potential mechanism of action for *C. fleckeri* venom activity {#sec9}
========================================================================================

Interest in the cardiotoxic molecular mechanism of *C. fleckeri* venom led to an *in vitro* study on the contractile force of isolated cardiac cells and membrane potentials ([@bib44]). The administration of *C. fleckeri* whole venom led to large increased intracellular calcium influx which caused spontaneous contractions, a decrease in developed force and an increase in resting force. Since calcium is vital for atrial contraction, calcium ion channels were thought to be responsible for this intense cardiac response. The response of papillary muscle contractility was not attenuated with the L-type calcium channel blockers Nifedipine, TTX or the sarcoplasmic reticulum inhibitor (Ryanodine). The isolated myocytes increased intracellular sodium concentrations preceding a large calcium influx. The study then preincubated papillary muscles with Ni^2+^ to block *C. fleckeri* venom effects. Ni^2+^ significantly attenuated the effect of *C. fleckeri* venom. This result led to the hypothesis that *C. fleckeri* venom could be acting through the activation of an Na^+^/Ca^2+^ exchanger. The study concluded that it was unlikely that the increase in Ca^2+^ was due to nonspecific membrane damage given the effects appeared so quickly after venom exposure.

An early study of *C. fleckeri* venom used anaesthetised Wistar rats (*Rattus norvegicus*) to monitor arterial and venous pressure, heart rate and abdominal respiratory movements ([@bib29]). The cause of death was from cardiotoxicity which was supported by interference with repolarization and conduction of atrial action potentials. It was reported that the toxin was haemolytic. Elevated plasma potassium was not consistently high enough to be related to the cardiac irregularities ([@bib52]). The study concluded that the venom likely alters membrane permeability ([@bib29]). A more recent study used isolated rat aorta to measure the vascular effects of *C. fleckeri* venom ([@bib59]). A venom titration produced a concentration independent sustained contraction of the endothelium-denuded aortic tissue. This study attempted to block the effects of the venom with Felodipine, which significantly reduced coronary flow velocity. Due to the positive effects of Felodipine treatment *in vitro*, the study speculated an ionophoric mechanism of action may be responsible for the effects of *C. fleckeri* venom.

Further studies on the molecular mechanism of *C. fleckeri* venom sought to confirm the increase of cytosolic calcium in myocytes as a cause for cardiotoxicity ([@bib3]). Here, cardiac ventricular myocytes were isolated and treated with a Indo-1 Ca^2+^ indicator dye before the addition of *C. fleckeri* venom. Cells pre-incubated with either lanthanum chloride or Verapamil prior were then exposed to *C. fleckeri* venom ([@bib3]). *Chironex fleckeri* venom caused an increase in free cytosolic Ca^2+^. *C. fleckeri* venom applied to myocytes preincubated with Verapamil resulted in an increase in free cytosolic Ca^2+^. *C. fleckeri* venom applied to preincubated myocytes with lanthanum caused an increase in free cytosolic Ca^2+^. Thus, the study showed that *C. fleckeri* venom did cause an increase in cytosolic calcium levels. To further investigate the source responsible for increased cytosolic calcium ions (i.e. intracellular or extracellular stores of calcium), manganese (Mn^2+^) Fura-2 quench reactions were performed. Mn^2+^ passes through the cell membrane using the same ion channels as Ca^2+^. The Mn^2+^ experiment determined that there was a notable permeability of Ca^2+^ into the myocytes under resting conditions. Venom dramatically increased the rate of extracellular Mn^2+^ influx into the cell. Thus, the increase in cytosolic Ca^2+^ is likely originating from the extracellular fluid via ion channels ([@bib3]). This was an important finding as it was previously thought the sarcoplasmic reticulum was the source of excess cytosolic calcium ([@bib44]). Overall, several studies have proposed that different fractions of *C. fleckeri* venom have different mechanisms of action ([@bib28]; [@bib19]; [@bib50]). While the established mechanism for *C. fleckeri* venom pathology is proposed to be ionophoric-based ([@bib3], [@bib29], [@bib44], [@bib59]), the exact voltage gated ion channels involved are unknown. Further research is required to confirm that calcium enters from the cell versus the extra cellular space ([@bib3]).

Three studies have tested three compounds (Nifedepine, Verapamil and Felodipine) all which were voltage gated calcium channel blockers. Only one compound (Nifedepine) was unable to attenuate *C. fleckeri* venom response ([@bib44]). Nifedepine inhibits L-type channels but does block other members of the calcium ion channels families. Of these calcium channel blockers, only Verapamil has been tested in human envenomation ([@bib22]). Felodipine has been tested *in vitro* and was shown to have some efficacy ([@bib59]).

Finally, a very recent study also suggests that *C. fleckeri* venom likely has several more mechanisms of action ([@bib62]). Using a genome-scale CRISPR knockout (GeCKO) screen, plasma membrane lipids were identified as key components in the cytotoxicity mechanism. Through the use of methyl-β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrins, which deplete cholesterol from the cell membrane, researchers were able to attenuate the venom response in human cell lines. Treatment with cyclodextrins attenuated both necrosis and pain when administered after venom in animal models.

10. Future directions and conclusion {#sec10}
====================================

Animal studies have laid the ground work for understanding the mechanism of action of *C. fleckeri* venom. Across the literature, treatment and survival are highly variable in animal experiments. Improvements could be made in the future by adopting a standardisation of venom preparation as previous described ([@bib17]). This would be key in facilitating more robust conclusions across different sites. Future studies should also report the venom profile by SDS, HPLC, FPLC or LC/MS/MS for quality control. Additionally, since cardiotoxicity is well characterised by ion channel disruption, monitoring the effects of the venom on the ion channels of primary afferent (pain sensing) neurons may be a logical place for future studies to begin characterizing the pain aspect of envenomation. Another consideration for future studies would be to use *C. fleckeri* venom to map pain pathways, as severe pain is a hallmark clinical symptom.

As described above, it has been reported that *C. fleckeri* antivenom is ineffective *in vivo*. Additionally, it remains unclear if *C. fleckeri* antivenom can mitigate clinical symptoms. A number of studies have found that the antivenom may opsonize the venom if premixed. However, these approaches are not practical. The venom extraction studies agreed that *C. fleckeri* venom was susceptible to heat and ([@bib16], [@bib15a]). The varying conditions in venom extraction can cause active proteins to denature and/or aggregate dramatically altering the venoms' potency ([@bib26], [@bib46]). Future studies should use the most non-invasive extraction technique that minimizes venom exposure to temperature changes and severe mechanical disruption. The cold mechanical extraction technique meets these requirements.

Additional omics work is needed. A full genome *C. fleckeri* sequence analysis has yet to be performed, nor detailed analysis of PTMs, small molecules, lipids or polysaccharides. Finally, marine phyla are highly underrepresented in current protein and nucleotide databases. More information is needed given the species diversity in Earth\'s oceans.

To better the understand mechanism of action of *C. fleckeri* venom, further ion channel physiology experiments are required. Future research should utilize new high-throughput techniques ([@bib34], [@bib56]). *In vitro* treatments that attenuate *C. fleckeri* venom activity have been based on the assumption of ionophoric activity. Since calcium ion conductance from the extracellular fluid has been confirmed to occur upon *C. fleckeri* venom exposure, future research should investigate the involvement of the other voltage gated calcium ion channels ([@bib28]).

In conclusion, the studies have contributed invaluable information on the mechanism of action of *C. fleckeri* venom and has revealed areas where future work is needed. Animal experiments have been crucial in understanding the mammalian physiological response. Antivenom studies have given key insights to the rapid kinetics of *C. fleckeri* venom and have highlighted that more work is needed to improve efficacy. Venom extraction studies have helped emphasise data inconsistencies across sites and have highlighted the need for a standardised protocol for venom extraction and profiling. Omics and CRISPR studies are beginning to allow a very comprehensive look on mechanism of action. Collectively, these studies will assist in the development of novel treatments for *C. fleckeri* envenomation and potentially, the discovery of novel cell pathways and scaffolds for next generation pharmaceuticals ([@bib38]).
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